Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) are a novel class of antidiabetic medications that confer protective effects on the cardiovascular system and kidneys and possibly the respiratory system.9,10,11,12 Animal studies have shown SGLT2Is to inhibit NLR pyrin domain containing protein 3 (NLRP3) inflammasome activation in multiple tissues, including the heart,13 liver,14 kidney,15 and lung.16 Inhibition of the NLRP3 inflammasome has been implicated in both improved asthmatic airway inflammation17 and COPD exacerbations.18 Therefore, SGLT2Is may potentially affect OAD. Here, NLRP3 is linked to chronic obstructive pulmonary disease.